Bronte Capital Management Pty Ltd. Acquires 3,890 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Bronte Capital Management Pty Ltd. lifted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 11.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 38,864 shares of the biopharmaceutical company’s stock after purchasing an additional 3,890 shares during the period. Alnylam Pharmaceuticals comprises approximately 1.7% of Bronte Capital Management Pty Ltd.’s investment portfolio, making the stock its 11th largest holding. Bronte Capital Management Pty Ltd.’s holdings in Alnylam Pharmaceuticals were worth $15,454,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in Alnylam Pharmaceuticals by 2.0% in the 3rd quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock valued at $6,185,846,000 after acquiring an additional 268,313 shares during the period. Capital Research Global Investors raised its stake in Alnylam Pharmaceuticals by 0.4% in the 3rd quarter. Capital Research Global Investors now owns 7,222,840 shares of the biopharmaceutical company’s stock valued at $3,293,516,000 after acquiring an additional 31,184 shares during the period. Groupama Asset Managment raised its stake in Alnylam Pharmaceuticals by 160.4% in the 3rd quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock valued at $18,610,000 after acquiring an additional 2,483,697 shares during the period. Orbis Allan Gray Ltd raised its stake in Alnylam Pharmaceuticals by 29.8% in the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock valued at $691,771,000 after acquiring an additional 486,489 shares during the period. Finally, Arrowstreet Capital Limited Partnership raised its stake in Alnylam Pharmaceuticals by 698.8% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company’s stock valued at $618,158,000 after acquiring an additional 1,185,909 shares during the period. 92.97% of the stock is currently owned by institutional investors.

Insider Activity

In other news, EVP Jeffrey V. Poulton sold 2,206 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $327.65, for a total transaction of $722,795.90. Following the sale, the executive vice president directly owned 64,273 shares in the company, valued at $21,059,048.45. This represents a 3.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Tolga Tanguler sold 1,598 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $327.65, for a total value of $523,584.70. Following the sale, the executive vice president owned 36,606 shares in the company, valued at approximately $11,993,955.90. This represents a 4.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 38,656 shares of company stock valued at $12,370,696. 0.86% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Trading Up 1.1%

Shares of ALNY opened at $301.11 on Wednesday. The business’s 50-day moving average price is $319.41 and its 200-day moving average price is $374.99. Alnylam Pharmaceuticals, Inc. has a twelve month low of $245.96 and a twelve month high of $495.55. The stock has a market cap of $40.20 billion, a PE ratio of 82.27 and a beta of 0.31. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, beating the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The firm had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.12 billion. During the same period in the prior year, the business posted ($0.44) earnings per share. The company’s revenue was up 96.4% on a year-over-year basis. On average, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post 6.78 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on ALNY shares. Raymond James Financial restated an “outperform” rating and issued a $472.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, January 12th. Chardan Capital restated a “buy” rating and issued a $425.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 25th. Jefferies Financial Group restated a “hold” rating and issued a $330.00 price objective (down from $522.00) on shares of Alnylam Pharmaceuticals in a research note on Monday, March 16th. Wall Street Zen upgraded Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Truist Financial lowered their price objective on Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating on the stock in a research note on Monday, April 13th. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $471.96.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.